EMAS position statement: Managing the menopause in women with a past history of endometriosis

Moen MH, Mette H Moen, Mette Haase Moen, Margaret Rees, Rees M, Brincat M, Marc Brincat, C. Tamer Erel, Tamer Erel, Gambacciani M, Marco Gambacciani, Irene Lambrinoudaki, Ιrene Lambrinoudaki, Karin Schenck-Gustafsson, Karin Schenck‐Gustafsson, Florence Tremollieres, Florence Trémollières, Tremollieres F, Svetlana Vujović, Vujovic S, Svetlana Vujovic, Serge Rozenberg, European Menopause and Andropause Society
Maturitas · 2010 · vol. 67(1) , pp. 94–97 · doi:10.1016/j.maturitas.2010.04.018 · PMID:20627430 · W2039322698
article OA: bronze CC0 ⤵ 46 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This position statement provides guidance on managing menopause in women with a prior history of endometriosis, considering hormone therapy and other treatment options.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

IntroductionEndometriosis is a common disease in women of reproductive age. The symptoms usually disappear after a natural or a surgical menopause. Estrogen-based hormone therapy is required in women with premature or early menopause until the average age of the natural menopause and should be considered in older women with severe climacteric symptoms. However use of hormone therapy raises concerns about disease recurrence with pain symptoms, need for surgery and possibly malignant transformation of residual endometriosis.AimTo formulate a position statement on the management of the menopause in women with a past history of endometriosis.Materials and methodsLiterature review and consensus of expert opinion.Results and conclusionsThe data regarding hormone therapy regimens are limited. However it may be safer to give either continuous combined estrogen-progestogen therapies or tibolone in both hysterectomised and nonhysterectomised women as the risk of recurrence may be reduced. The risk of recurrence with hormone therapy is probably increased in women with residual disease after surgery. Management of potential recurrence is best monitored by responding to recurrence of symptoms. Women not wanting estrogen or those who are advised against should be offered alternative pharmacological treatment for climacteric symptoms or skeletal protection if indicated. Herbal preparations should be avoided as their efficacy is uncertain and some may contain estrogenic compounds.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Estrogen Receptor Modulators Estrogen Replacement Therapy Estrogen Replacement Therapy Menopause Menopause, Premature Norpregnenes Endometriosis Estrogen Receptor Modulators Female Humans Hysterectomy Norpregnenes Recurrence

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (46)

Cited by (47)

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:07.008521+00:00
License: CC0 · commercial use OK